Bifidobacterium longum with Fructo-Oligosaccharides in Patients with Non Alcoholic Steatohepatitis
- 2011-09-08
- Digestive Diseases and Sciences 57(2)
- M. Malaguarnera
- M. Vacante
- T. Antić
- M. Giordano
- G. Chisari
- R. Acquaviva
- S. Mastrojeni
- G. Malaguarnera
- A. Mistretta
- G. Volti
- F. Galvano
- PubMed: 21901256
- DOI: 10.1007/s10620-011-1887-4
Abstract
Background: Increased exposure to intestinal bacterial products may contribute to the pathogenesis of non alcoholic steatohepatitis (NASH). Bifidobacteria are predominant bacterial species in the human gut microbiota and have been considered to exert a beneficial effect on human health by maintaining the equilibrium of the resident microbiota.
Aims: To evaluate the effects of Bifidobacterium longum with fructo-oligosaccharides (Fos) in the treatment of NASH.
Methods: A total of 66 patients were randomly and equally divided into two groups receiving Bifidobacterium longum with Fos and lifestyle modification (i.e., diet and exercise) versus lifestyle modification alone. The following variables were assessed at -4 (beginning of the dietary lead-in period), 0 (randomization), 6, 12, 18, and 24 weeks: aspartate transaminase (AST), alanine transaminase (ALT), bilirubin, albumin, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, fasting plasma glucose, insulin, C-peptide, C-reactive protein (CRP), tumor necrosis factor (TNF)-α, homeostasis model assessment of insulin resistance (HOMA-IR), and serum endotoxins. Liver biopsies were performed at entry and repeated after 24 weeks of treatment.
Results: At the end of study period, we observed that the Bifidobacterium longum with Fos and lifestyle modification group versus the lifestyle modification alone group showed significant differences in the AST -69.6 versus -45.9 IU/mL (P < 0.05), LDL cholesterol -0.84 versus -0.18 mmol/L (P < 0.001), CRP -2.9 versus -0.7 mg/L (P < 0.05), TNF-α -0.45 versus -0.12 ng/mL (P < 0.001), HOMA-IR -1.1 versus -0.6 (P < 0.001), serum endotoxin -45.2 versus -30.6 pg/mL (P < 0.001), steatosis (P < 0.05), and the NASH activity index (P < 0.05).
Conclusions: Bifidobacterium longum with Fos and lifestyle modification, when compared to lifestyle modification alone, significantly reduces TNF-α, CRP, serum AST levels, HOMA-IR, serum endotoxin, steatosis, and the NASH activity index.
Research Insights
| Supplement | Health Outcome | Effect Type | Effect Size |
|---|---|---|---|
| Bifidobacterium lactis/longum | Improved Insulin Sensitivity | Beneficial | Large |
| Bifidobacterium lactis/longum | Reduced AST Levels | Beneficial | Moderate |
| Bifidobacterium lactis/longum | Reduced C-Reactive Protein Levels | Beneficial | Moderate |
| Bifidobacterium lactis/longum | Reduced Liver Fat | Beneficial | Moderate |
| Bifidobacterium lactis/longum | Reduced NASH Activity Index | Beneficial | Moderate |
| Bifidobacterium lactis/longum | Reduced Serum LPS Levels | Beneficial | Large |
| Bifidobacterium lactis/longum | Reduced TNF-α Levels | Beneficial | Large |
| Bifidobacterium longum B1-05 | Improved Insulin Sensitivity | Beneficial | Large |
| Bifidobacterium longum B1-05 | Improved Liver Steatosis | Beneficial | Moderate |
| Bifidobacterium longum B1-05 | Reduced Aminotransferase Levels | Beneficial | Moderate |
| Bifidobacterium longum B1-05 | Reduced C-Reactive Protein Levels | Beneficial | Moderate |
| Bifidobacterium longum B1-05 | Reduced Low-Density Lipoprotein Level | Beneficial | Large |
| Bifidobacterium longum B1-05 | Reduced NASH Activity | Beneficial | Moderate |
| Bifidobacterium longum B1-05 | Reduced Serum LPS Levels | Beneficial | Large |
| Bifidobacterium longum B1-05 | Reduced Tumor Necrosis Factor Alpha | Beneficial | Large |
| Bifidobacterium longum BI-05 | Improved Insulin Sensitivity | Beneficial | Large |
| Bifidobacterium longum BI-05 | Improved Liver Steatosis | Beneficial | Moderate |
| Bifidobacterium longum BI-05 | Reduced AST Levels | Beneficial | Moderate |
| Bifidobacterium longum BI-05 | Reduced C-Reactive Protein Levels | Beneficial | Moderate |
| Bifidobacterium longum BI-05 | Reduced NASH Activity Index | Beneficial | Moderate |
| Bifidobacterium longum BI-05 | Reduced Serum LPS Levels | Beneficial | Large |
| Bifidobacterium longum BI-05 | Reduced TNF-α Levels | Beneficial | Large |
| Bifidobacterium longum HA-135 | Improved Insulin Sensitivity | Beneficial | Large |
| Bifidobacterium longum HA-135 | Improved Liver Steatosis | Beneficial | Moderate |
| Bifidobacterium longum HA-135 | Reduced Aspartate Transaminase Activity | Beneficial | Moderate |
| Bifidobacterium longum HA-135 | Reduced C-Reactive Protein Levels | Beneficial | Moderate |
| Bifidobacterium longum HA-135 | Reduced LDL Cholesterol | Beneficial | Large |
| Bifidobacterium longum HA-135 | Reduced NASH Activity | Beneficial | Moderate |
| Bifidobacterium longum HA-135 | Reduced Serum LPS Levels | Beneficial | Large |
| Bifidobacterium longum HA-135 | Reduced Tumor Necrosis Factor Alpha | Beneficial | Large |
| Bifidobacterium longum KABP-042 | Improved Insulin Sensitivity | Beneficial | Large |
| Bifidobacterium longum KABP-042 | Reduced AST Levels | Beneficial | Moderate |
| Bifidobacterium longum KABP-042 | Reduced C-Reactive Protein Levels | Beneficial | Moderate |
| Bifidobacterium longum KABP-042 | Reduced LDL Cholesterol | Beneficial | Large |
| Bifidobacterium longum KABP-042 | Reduced Liver Fat | Beneficial | Moderate |
| Bifidobacterium longum KABP-042 | Reduced Serum LPS Levels | Beneficial | Large |
| Bifidobacterium longum KABP-042 | Reduced Tumor Necrosis Factor Alpha | Beneficial | Large |
| Bifidobacterium longum MAK34B12L | Improved Insulin Sensitivity | Beneficial | Large |
| Bifidobacterium longum MAK34B12L | Improved Liver Steatosis | Beneficial | Moderate |
| Bifidobacterium longum MAK34B12L | Reduced AST Levels | Beneficial | Moderate |
| Bifidobacterium longum MAK34B12L | Reduced C-Reactive Protein Levels | Beneficial | Moderate |
| Bifidobacterium longum MAK34B12L | Reduced LDL Cholesterol | Beneficial | Large |
| Bifidobacterium longum MAK34B12L | Reduced NASH Activity | Beneficial | Moderate |
| Bifidobacterium longum MAK34B12L | Reduced Serum Endotoxin Levels | Beneficial | Large |
| Bifidobacterium longum MAK34B12L | Reduced TNF-α Levels | Beneficial | Large |
| Bifidobacterium longum MM-2 | Improved Insulin Sensitivity | Beneficial | Large |
| Bifidobacterium longum MM-2 | Improved Liver Steatosis | Beneficial | Moderate |
| Bifidobacterium longum MM-2 | Reduced AST Levels | Beneficial | Moderate |
| Bifidobacterium longum MM-2 | Reduced C-Reactive Protein Levels | Beneficial | Moderate |
| Bifidobacterium longum MM-2 | Reduced LDL Cholesterol | Beneficial | Large |
| Bifidobacterium longum MM-2 | Reduced NASH Activity Index | Beneficial | Moderate |
| Bifidobacterium longum MM-2 | Reduced Serum LPS Levels | Beneficial | Large |
| Bifidobacterium longum MM-2 | Reduced TNF-α Levels | Beneficial | Large |
| Bifidobacterium longum Rosell-175 | Improved Insulin Sensitivity | Beneficial | Large |
| Bifidobacterium longum Rosell-175 | Improved Liver Steatosis | Beneficial | Moderate |
| Bifidobacterium longum Rosell-175 | Reduced Aspartate Transaminase Activity | Beneficial | Moderate |
| Bifidobacterium longum Rosell-175 | Reduced C-Reactive Protein Levels | Beneficial | Moderate |
| Bifidobacterium longum Rosell-175 | Reduced Low-Density Lipoprotein Level | Beneficial | Large |
| Bifidobacterium longum Rosell-175 | Reduced NASH Activity Index | Beneficial | Moderate |
| Bifidobacterium longum Rosell-175 | Reduced Serum LPS Levels | Beneficial | Large |
| Bifidobacterium longum Rosell-175 | Reduced Tumor Necrosis Factor Alpha | Beneficial | Large |
| Bifidobacterium longum SD-5588 | Improved Insulin Sensitivity | Beneficial | Large |
| Bifidobacterium longum SD-5588 | Reduced Aspartate Transaminase Activity | Beneficial | Moderate |
| Bifidobacterium longum SD-5588 | Reduced C-Reactive Protein Levels | Beneficial | Moderate |
| Bifidobacterium longum SD-5588 | Reduced Hepatic Steatosis | Beneficial | Moderate |
| Bifidobacterium longum SD-5588 | Reduced LDL Cholesterol | Beneficial | Large |
| Bifidobacterium longum SD-5588 | Reduced Serum LPS Levels | Beneficial | Large |
| Bifidobacterium longum SD-5588 | Reduced Tumor Necrosis Factor Alpha | Beneficial | Large |
| Bifidobacterium longum SP54 | Improved Insulin Sensitivity | Beneficial | Large |
| Bifidobacterium longum SP54 | Reduced AST Levels | Beneficial | Moderate |
| Bifidobacterium longum SP54 | Reduced C-Reactive Protein Levels | Beneficial | Moderate |
| Bifidobacterium longum SP54 | Reduced LDL Cholesterol | Beneficial | Large |
| Bifidobacterium longum SP54 | Reduced Liver Fat | Beneficial | Moderate |
| Bifidobacterium longum SP54 | Reduced Serum LPS Levels | Beneficial | Large |
| Bifidobacterium longum SP54 | Reduced TNF-α Levels | Beneficial | Large |
| Bifidobacterium longum UABI-14 | Improved Insulin Sensitivity | Beneficial | Large |
| Bifidobacterium longum UABI-14 | Improved Liver Steatosis | Beneficial | Moderate |
| Bifidobacterium longum UABI-14 | Reduced Aspartate Transaminase Activity | Beneficial | Moderate |
| Bifidobacterium longum UABI-14 | Reduced C-Reactive Protein Levels | Beneficial | Moderate |
| Bifidobacterium longum UABI-14 | Reduced Low-Density Lipoprotein Level | Beneficial | Large |
| Bifidobacterium longum UABI-14 | Reduced NASH Activity Index | Beneficial | Moderate |
| Bifidobacterium longum UABI-14 | Reduced Serum LPS Levels | Beneficial | Large |
| Bifidobacterium longum UABI-14 | Reduced Tumor Necrosis Factor Alpha | Beneficial | Large |
| Bifidobacterium longum UABl-14 | Improved Insulin Sensitivity | Beneficial | Large |
| Bifidobacterium longum UABl-14 | Improved Liver Steatosis | Beneficial | Moderate |
| Bifidobacterium longum UABl-14 | Reduced Aminotransferase Levels | Beneficial | Moderate |
| Bifidobacterium longum UABl-14 | Reduced C-Reactive Protein Levels | Beneficial | Moderate |
| Bifidobacterium longum UABl-14 | Reduced Low-Density Lipoprotein Level | Beneficial | Large |
| Bifidobacterium longum UABl-14 | Reduced Serum LPS Levels | Beneficial | Large |
| Bifidobacterium longum UABl-14 | Reduced Tumor Necrosis Factor Alpha | Beneficial | Large |